中国生物制药(01177)公布，有关F-star所有已发行及发行在外的股份的收购事项已于2023年3月8日(美国东部时间)成功完成，总现金代价约1.61亿美元。要约收购于2023年3月8日下午五时正(美国东部时间)届满后，要约收购交割的所有条件已获达成，Fennec已就收购要约中有效交回且尚未适当撤回的所有目标股份支付存管处。于2023年3月8日，要约收购交割后，Fennec透过根据特拉华州普通公司法第251(h)条的合并收购要约收购中尚未收购的余下目标股份。合并后，目标股份将于纳斯达克除牌。所规定的监管审查已取得，包括来自英国国家安全和投资法(NSIA)以及美国外国投资委员会(CFIUS)的批准。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.